Delving into the Latest Updates on NK510 with Synapse

Overview

Basic Info

Drug Type

Natural Killer Cell Therapies, Gene editing

Synonyms

BED-NK

Target-

Mechanism-

Therapeutic Areas

NeoplasmsDigestive System DisordersSkin and Musculoskeletal Diseases+ [3]

Active Indication

Advanced gastric carcinomaNon-Small Cell Lung CancerOsteosarcoma+ [4]

Inactive Indication

Acute Myeloid LeukemiaLiver Cancer

Originator Organization

Base Therapeutics (Zhuhai) Ltd.

Active Organization

Base Therapeutics (Shanghai) Ltd.

Base Therapeutics (Zhuhai) Ltd.

Inactive Organization-

Drug Highest PhaseEarly Phase 1

First Approval Date-

Regulation-

Login to view timeline

This study will evaluate the safety and efficacy of NK510 in the treatment of relapsed and refractory advanced gastric cancer.NK510 will be administered in combination with PD-1 blockade or monoclonal anti-HER2 antibody. Patients are required to undergo a biopsy for confirmation of tumor PD-L1 and HER2 expression and. The safety and efficacy of this treatment will be evaluated.

Start Date01 Nov 2023

Sponsor / Collaborator

Base Therapeutics (Shanghai) Ltd.

NCT06097962 / RecruitingEarly Phase 1

Exploratory Study of NK510 Combined With PD-1 Blockade in the Treatment of Relapsed and Refractory Advanced NSCLC

This study will evaluate the safety and efficacy of NK510 in the treatment of relapsed and refractory advanced NSCLC.NK510 will be administered in combination with PD-1 blockade. Patients are required to undergo a biopsy for confirmation of tumor PD-L1 expression,and EGFR,ROS1,ALK gene must be negative. The safety and efficacy of this treatment will be evaluated.

Start Date01 Jul 2023

Sponsor / Collaborator

Base Therapeutics (Shanghai) Ltd.

NCT06117878 / RecruitingEarly Phase 1

An Open, Single Center Exploratory Study to Evaluate Safety and Efficacy of NK510 for Patients With Osteosarcoma and Soft Tissue Sarcoma

This study will evaluate the safety and efficacy of NK510 in the treatment of Osteosarcoma and Soft Tissue Sarcoma.NK510 will be administered by intravenous injection. The safety and efficacy of this treatment will be evaluated.

Start Date01 Sep 2022

Sponsor / Collaborator

Base Therapeutics (Shanghai) Ltd.

[+1]

100 Clinical Results associated with NK510

Login to view more data

100 Translational Medicine associated with NK510

Login to view more data

100 Patents (Medical) associated with NK510

Login to view more data

100 Deals associated with NK510

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Myeloid Leukemia	Phase 2	CN	Base Therapeutics (Zhuhai) Ltd.	17 Apr 2023
Liver Cancer	Phase 2	CN	Base Therapeutics (Zhuhai) Ltd.	17 Apr 2023
Advanced gastric carcinoma	Phase 1	CN	Base Therapeutics (Shanghai) Ltd.	01 Nov 2023
Non-Small Cell Lung Cancer	Phase 1	CN	Base Therapeutics (Shanghai) Ltd.	01 Jul 2023
Osteosarcoma	Phase 1	CN	Base Therapeutics (Shanghai) Ltd.	01 Sep 2022
Soft Tissue Sarcoma	Phase 1	CN	Base Therapeutics (Shanghai) Ltd.	01 Sep 2022
Advanced Malignant Solid Neoplasm	IND Approval	CN	Base Therapeutics (Zhuhai) Ltd.	22 Oct 2024
Advanced Malignant Solid Neoplasm	IND Approval	CN	Base Therapeutics (Shanghai) Ltd.	22 Oct 2024
Systemic Lupus Erythematosus	Preclinical	CN	Base Therapeutics (Zhuhai) Ltd.	14 Jun 2024
Sarcoma	Preclinical	CN	Base Therapeutics (Zhuhai) Ltd.	17 Apr 2023